查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018930

生物影像市場：按產品、技術、模式、應用和最終用戶分類－2026-2032年全球市場預測

Bio-imaging Market by Product, Technology, Modality, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物成像市場價值將達到 73.8 億美元，到 2026 年將成長到 81.3 億美元，到 2032 年將達到 149 億美元，複合年成長率為 10.55%。

主要市場統計數據
基準年 2025 73.8億美元
預計年份：2026年 81.3億美元
預測年份 2032 149億美元
複合年成長率 (%) 10.55%

清晰權威地闡述了整合成像技術、分析和臨床工作流程如何重塑診斷準確性和調查路徑。

生物影像領域正經歷著翻天覆地的變化，硬體、軟體和臨床整合的同步進步推動著這項變革。影像方式曾經各自獨立地應用於診斷和手術，如今正融合為混合工作流程，優先考慮診斷準確性、工作流程效率和資料互通性。臨床醫生和研究人員越來越重視影像衍生分析、縱向資料擷取和可重複的影像方案，以支持個人化醫療和轉化研究。

人工智慧整合、模態混合、基於雲端的協作和流程去中心化如何共同重新定義生物成像領域的臨床工作流程和商業化模式。

影像產業正經歷一場變革性的轉變，不再侷限於產品效能的漸進式改進，而是從系統層面改變診斷影像的執行、分析和報銷方式。人工智慧 (AI) 和機器學習已從概念驗證(PoC) 模型發展成為嵌入式工具，能夠增強放射科醫生的工作流程，自動化常規影像處理任務，並提取臨床可用的生物標記。因此，人們的關注點集中在模型檢驗、監管核准流程以及如何將 AI 輸出整合到臨床決策支援系統中。

評估 2025 年貿易政策變化對影像相關人員供應鏈韌性、區域製造策略和採購決策的策略影響。

2025年的關稅狀況​​為全球醫療影像硬體、組件和耗材的供應鏈和採購決策帶來了新的複雜性。進口關稅的增加和貿易政策的調整可能會推高依賴海外組件的系統總成本，迫使製造商重新評估其供應商所在地和製造地。為此，許多公司正在加快供應商多元化進程，並選擇替代組件來源，以維持生產的連續性並確保獲利能力。

將特定模式的創新、產品組合、應用需求和最終用戶採購行為與商業性機會連結起來的策略性細分洞察。

細分市場分析揭示了技術、產品、模式、應用和最終用戶等維度上創新與商業性機會的交匯點。從技術層面來看，磁振造影(MRI) 和 X 光成像等成熟模式仍是診斷的核心，而內視鏡、核子醫學影像、手術顯微鏡和超音波技術則透過解析度、便攜性和整合性的提升，不斷拓展其臨床應用範圍。這種技術多樣性要求供應商開發針對特定模式的臨床工作流程和報銷趨勢的價值提案。

美洲、歐洲、中東、非洲和亞太地區的區域戰略趨勢和獨特的實施模式，決定了針對每個地區量身定做的商業化和監管方法。

區域趨勢正顯著影響著美洲、歐洲、中東和非洲以及亞太地區的採用模式、監管路徑和商業性策略。在美洲，由於醫院網路整合以及對門診和日間護理設施投資的增加，醫療保健系統對先進診斷能力和軟體主導的效率提升有著強勁的需求。這種環境推動了能夠展現臨床療效並降低營運成本的整合解決方案的發展，而報銷趨勢和監管考量則影響這些解決方案的採用速度。

本報告揭示了成熟企業、創新者和軟體專家如何透過夥伴關係、併購和證據生成進行協作，從而在生物成像領域建立競爭優勢，並重點介紹了競爭和合作的商業趨勢。

生物成像領域的競爭格局由成熟的跨國公司、敏捷的醫療設備創新者和專業軟體供應商組成。成熟的製造商擁有規模優勢、龐大的基本客群和豐富的監管合規經驗，這些優勢支撐著高價設備銷售和長期服務合約。同時，中小企業和Start-Ups正在迅速推出影像分析、雲端原生資料管理和照護現場設備等方面的顛覆性功能，並透過夥伴關係、授權協議和有針對性的收購來加速自身能力建設。

為領導者提供切實可行的策略指導，以加強供應鏈韌性，加速成熟人工智慧的採用，並使模組化商業化適應當地市場實際情況。

產業領導者應推動一系列合作舉措，將技術潛力轉化為永續的商業性優勢。首先，實現供應鏈多元化，並對跨區域的製造合作夥伴進行認證，以降低貿易政策波動和關鍵零件短缺的風險。其次，優先發展模組化產品設計和服務，以實現更快的升級、更便利的維護，並提供多樣化的資金籌措模式，以滿足門診診所、診斷中心和醫院的採購需求。第三，加快對檢驗的人工智慧和分析技術的投資，重點關注可解釋性、臨床檢驗和合規性，以增強臨床醫生的信心並獲得支付方的認可。

嚴謹的多方法研究設計，結合一手訪談、第二手資料整合和反覆檢驗，確保為相關人員。

本研究整合了定性和定量相結合的多方面研究方法。初步調查包括對臨床負責人、採購負責人、技術主管和監管專家進行結構化訪談和情境研討會，以識別挑戰、應用促進因素和商業優先事項。第二次調查包括對同行評審文獻、監管申報文件、臨床指南和技術白皮書進行系統性回顧，以了解技術趨勢和證據要求。

隨著生物影像技術改變臨床護理和研究，綜合技術、檢驗的證據和在地化策略簡潔地整合了決定誰能獲得價值的機制。

總而言之，生物成像正處於轉折點，技術進步必須與切實可行的商業化策略相契合。先進的影像模式、人工智慧驅動分析以及雲端原生資料架構的融合，在釋放新的臨床能力的同時，也提高了人們對證據、互通性和資料管治的期望。監管的複雜性和地緣政治貿易動態為戰略考量增添了新的層面，迫使各組織調整供應鏈、加速臨床檢驗並完善經營模式。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物影像市場：依產品分類

  • 影像系統
  • 裝置
    • CT掃描儀
    • 核磁共振造影系統
    • 超音波設備
  • 試劑
  • 軟體
    • 資料管理軟體
    • 影像分析軟體

第9章：生物影像市場：依技術分類

  • 內視鏡
  • 磁振造影
  • 核子醫學掃描術診斷
  • 手術顯微鏡
  • 超音波
  • X光影像診斷

第10章：生物影像市場：依影像方式分類

  • 2D成像
  • 3D成像

第11章：生物造影市場：按應用領域分類

  • 臨床診斷
  • 藥物發現
  • 研究
  • 治療

第12章 生物影像市場：依最終用戶分類

  • 門診手術中心
  • 診斷影像中心
  • 醫院和診所

第13章：生物影像市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：生物影像市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：生物影像市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國生物影像市場

第17章：中國生物成像市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BaySpec, Inc.
  • Bracco SpA
  • Bruker Corporation
  • Canon Medical Systems Corporation
  • Digirad Corporation
  • Esaote SpA
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hitachi Medical Corporation
  • HT BioImaging Ltd
  • iThera Medical GmbH
  • Kitware, Inc.
  • Koninklijke Philips NV
  • Lantheus Medical Imaging, Inc.
  • M Squared Lasers Ltd.
  • MARS Bioimaging Limited
  • Medtronic PLC
  • MobileODT Ltd by Liger Medical LLC
  • Perspectum Ltd.
  • Quibim, SL
  • RadNet, Inc.
  • Rivanna Medical, Inc.
  • Samsung Medison Co., Ltd.
  • Siemens Healthineers
Product Code: MRR-710B1F0AC3D1

The Bio-imaging Market was valued at USD 7.38 billion in 2025 and is projected to grow to USD 8.13 billion in 2026, with a CAGR of 10.55%, reaching USD 14.90 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.38 billion
Estimated Year [2026] USD 8.13 billion
Forecast Year [2032] USD 14.90 billion
CAGR (%) 10.55%

A clear and authoritative framing of how convergent imaging technologies, analytics, and clinical workflows are reshaping diagnostic precision and research pathways

The bio-imaging landscape is undergoing a profound evolution driven by parallel advances in hardware, software, and clinical integration. Imaging modalities that were once siloed within diagnostic or surgical contexts are converging into hybrid workflows that prioritize diagnostic precision, workflow efficiency, and data interoperability. Clinicians and researchers alike are placing greater emphasis on image-derived analytics, longitudinal data capture, and reproducible imaging protocols to support personalized care and translational research.

Against this backdrop, investments in image analysis software, cloud-native data management, and device interoperability are reshaping procurement priorities across end users. These shifts are not merely technological; they reflect changing clinical pathways that integrate imaging more tightly into therapeutic decision-making and drug development pipelines. As a result, manufacturers and solution providers must align innovation strategies with evolving clinician needs, regulatory expectations, and payer-driven demands for demonstrable clinical value. This introduction frames the executive summary that follows, setting the stage for detailed discussion of market dynamics, policy impacts, segmentation nuances, regional variations, and recommended actions for leaders navigating this fast-evolving sector.

How AI integration, modality hybridization, cloud-enabled collaboration, and procedural decentralization are jointly redefining clinical workflows and commercialization models in bio-imaging

The industry is experiencing transformative shifts that extend beyond incremental product improvements to systemic changes in how imaging is performed, analyzed, and reimbursed. Artificial intelligence and machine learning have matured from proof-of-concept models into embedded tools that augment radiologist workflows, automate routine image processing tasks, and surface clinically actionable biomarkers. Consequently, attention has turned to model validation, regulatory approval pathways, and strategies to integrate AI outputs into clinical decision support systems.

Simultaneously, hybridization of modalities-where endoscopy is combined with high-resolution imaging, or ultrasound is augmented by contrast agents and AI interpretation-has expanded clinical utility across specialties. Cloud-based data management and secure federated learning approaches are enabling multi-institutional collaboration, while edge computing is facilitating near-patient inference for point-of-care diagnostics. Device miniaturization and advances in surgical microscopy are shifting procedures from inpatient to ambulatory and outpatient settings, altering purchasing cycles and capital planning. Collectively, these shifts demand that stakeholders adopt flexible commercialization models, invest in regulatory and evidence generation capabilities, and form partnerships that bridge hardware, software, and clinical services.

Assessing the strategic implications of 2025 trade policy changes on supply chain resilience, regional manufacturing strategies, and procurement decision-making across imaging stakeholders

The tariff landscape of 2025 has introduced new complexities into global supply chains and procurement decisions for imaging hardware, components, and consumables. Increased import duties and trade policy adjustments have the potential to raise landed costs for systems that rely on internationally sourced components, intensifying pressure on manufacturers to reassess supplier footprints and manufacturing locations. In response, many firms are accelerating supplier diversification and qualifying alternate component sources to sustain production continuity and preserve margin integrity.

Beyond direct cost implications, tariffs influence strategic choices about localization, inventory strategies, and pricing transparency with customers. Some vendors are evaluating regional assembly or final-stage manufacturing to mitigate tariff exposure while others are negotiating long-term supplier agreements to secure priority access to constrained components. Additionally, regulatory compliance and customs classification have become more prominent as companies seek to optimize tariff treatments and leverage trade facilitation mechanisms. The aggregate effect is a recalibration of procurement timelines, capital allocation, and partnership strategies as organizations adapt to a more fragmented and policy-sensitive trade environment.

Strategic segmentation insights that connect modality-specific innovation, product composition, application needs, and end-user procurement behavior to commercial opportunity

Segmentation analysis illuminates where innovation and commercial opportunity intersect across technology, product, modality, application, and end-user dimensions. When considering technology, mature modalities such as magnetic resonance imaging and X-ray imaging continue to be core diagnostic pillars, while endoscopy, nuclear imaging, surgical microscopy, and ultrasound are expanding their clinical reach through enhancements in resolution, portability, and integration. This technological diversity requires vendors to tailor value propositions that align with modality-specific clinical workflows and reimbursement dynamics.

Product segmentation reveals that imaging systems and instruments remain central to capital investment decisions, yet reagents and software are increasingly important as recurring revenue drivers and enablers of differentiated clinical outcomes. Within instruments, CT scanners, MRI machines, and ultrasound devices have distinct procurement cycles and service models that influence total cost of ownership conversations. Software divides broadly into data management platforms that address interoperability and security, and image analysis tools that deliver analytic insights; both categories play a growing role in vendor differentiation. Modality distinctions between 2D and 3D imaging underscore divergent requirements for image acquisition, storage, and interpretation, particularly in applications spanning clinical diagnostics, drug discovery, research, and therapeutics. End users such as ambulatory surgical centers, diagnostic imaging centers, and hospitals and clinics each prioritize different combinations of throughput, capital expense, and integration with electronic health records, shaping purchase criteria and post-sale service expectations. By interpreting segmentation through the lens of clinical workflows and purchasing behavior, organizations can better align product road maps and commercial models to specific demand drivers.

Regional strategic dynamics and differentiated adoption patterns across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform tailored commercialization and regulatory approaches

Regional dynamics materially influence adoption patterns, regulatory pathways, and commercial approaches across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, healthcare systems exhibit a strong appetite for advanced diagnostic capabilities and software-driven efficiency gains, supported by consolidated hospital networks and growing investment in outpatient and ambulatory care sites. This environment favors integrated solutions that demonstrate clinical impact and operational savings, while reimbursement dynamics and regulatory considerations guide the pace of adoption.

Europe Middle East & Africa presents a heterogeneous landscape where regulatory stringency, national health priorities, and infrastructure variability shape market entry strategies. Some markets emphasize centralized, high-quality imaging centers and national screening programs, prompting demand for scalable, interoperable solutions. Other markets are investing in capacity expansion and modernization, creating opportunities for modular systems and remote service offerings. Asia-Pacific is characterized by rapid expansion of diagnostic infrastructure, investments in local manufacturing, and strong interest in cost-effective, high-throughput technologies. Private healthcare growth and public initiatives to improve access to diagnostics are driving demand for both high-end modalities and portable point-of-care devices. Across regions, localization of service networks, compliance with regional regulatory frameworks, and culturally informed clinical validation are essential for successful commercialization. Understanding these regional distinctions enables targeted resource allocation and partnership selection to accelerate market penetration.

Competitive and collaborative company trends that reveal how incumbents, innovators, and software specialists are aligning through partnerships, M&A, and evidence generation to win in bio-imaging

Competitive dynamics in bio-imaging are shaped by a mix of legacy multinationals, nimble device innovators, and specialist software vendors. Legacy manufacturers retain strengths in scale, installed base service networks, and regulatory experience, which support large capital sales and long-term service agreements. At the same time, smaller firms and startups are rapidly introducing disruptive capabilities in image analysis, cloud-native data management, and point-of-care devices, prompting partnerships, licensing agreements, and targeted acquisitions to accelerate capability build-out.

Strategic collaborations between device OEMs and software companies are becoming more commonplace as hardware vendors seek to bundle analytic and data services that demonstrate measurable clinical value. Partnerships with academic medical centers and clinical research organizations are also essential for evidence generation and regulatory submissions. Moreover, companies that invest in robust post-market surveillance, cyber-security safeguards, and interoperability standards position themselves favorably with health systems that require secure, auditable data flows. The competitive landscape rewards firms that can integrate clinical validation, regulatory strategy, and go-to-market agility into a cohesive commercialization plan.

Actionable strategic guidance for leaders to enhance supply chain resilience, accelerate validated AI adoption, and align modular commercialization with regional market realities

Industry leaders should pursue a set of coordinated actions to translate technological promise into sustainable commercial advantage. First, diversify supply chains and qualify multi-regional manufacturing partners to reduce exposure to trade policy volatility and critical component shortages. Second, prioritize modular product design and services that enable faster upgrades, easier maintenance, and varied financing models adapted to ambulatory, diagnostic center, and hospital procurement preferences. Third, accelerate investment in validated AI and analytics, focusing on explainability, clinical validation, and regulatory alignment to build clinician trust and payer acceptance.

In parallel, strengthen strategic partnerships with software vendors, academic centers, and specialty service providers to co-develop evidence that links imaging outputs to improved patient outcomes. Implement robust data governance, cybersecurity, and interoperability frameworks to facilitate multi-institutional collaboration and secure cloud deployments. Finally, align commercialization plans with regional nuances by tailoring product configurations, service models, and reimbursement strategies to local market realities. These actions collectively reduce execution risk, increase adoption velocity, and create defensible differentiation in a competitive landscape.

Rigorous multi-method research design combining primary interviews, secondary evidence synthesis, and iterative validation to ensure robust, actionable insights for stakeholders

The study synthesizes insights from a multi-method research approach combining qualitative and quantitative techniques. Primary research consisted of structured interviews and scenario workshops with clinical leaders, procurement officers, technology executives, and regulatory specialists to surface pain points, adoption drivers, and commercial priorities. Secondary research involved a systematic review of peer-reviewed literature, regulatory filings, clinical guidelines, and technical whitepapers to contextualize technological trends and evidence requirements.

Data triangulation was used to reconcile insights across sources, while thematic analysis highlighted recurring adoption barriers and success factors. Validation exercises with external experts and iterative feedback loops ensured that conclusions reflect practical realities encountered by field stakeholders. Methodological rigor was maintained through transparent documentation of data sources, interview frameworks, and assumption checks, enabling reproducibility and confidence in the study's recommendations. Ethical considerations and confidentiality protocols were observed during primary engagements to protect proprietary information shared by participants.

Concise synthesis of how integrated technology, validated evidence, and regionally informed strategy will determine who captures value as bio-imaging transforms clinical care and research

In summary, bio-imaging stands at an inflection point where technological sophistication must be matched by pragmatic commercialization strategies. The convergence of advanced modalities, AI-enabled analytics, and cloud-native data architectures is unlocking new clinical capabilities while simultaneously raising expectations for evidence, interoperability, and data stewardship. Regulatory complexity and geopolitical trade dynamics add layers of strategic consideration, compelling organizations to adapt supply chains, accelerate clinical validation, and refine commercial models.

Decision-makers who act decisively to integrate validated software, modular hardware, and regionally attuned service models will be best positioned to capture value. Equally important is the ability to demonstrate measurable clinical and economic impact, which increasingly governs adoption and reimbursement. By aligning innovation road maps with clinician workflows, payer priorities, and regional regulatory contexts, stakeholders can convert technical advances into scalable clinical solutions that improve outcomes and operational efficiency.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bio-imaging Market, by Product

  • 8.1. Imaging Systems
  • 8.2. Instruments
    • 8.2.1. CT Scanners
    • 8.2.2. MRI Machines
    • 8.2.3. Ultrasound Devices
  • 8.3. Reagents
  • 8.4. Software
    • 8.4.1. Data Management Software
    • 8.4.2. Image Analysis Software

9. Bio-imaging Market, by Technology

  • 9.1. Endoscopy
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Nuclear Imaging
  • 9.4. Surgical Microscopy
  • 9.5. Ultrasound
  • 9.6. X-ray Imaging

10. Bio-imaging Market, by Modality

  • 10.1. 2D Imaging
  • 10.2. 3D Imaging

11. Bio-imaging Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery
  • 11.3. Research
  • 11.4. Therapeutics

12. Bio-imaging Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Imaging Centers
  • 12.3. Hospitals & Clinics

13. Bio-imaging Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bio-imaging Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bio-imaging Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bio-imaging Market

17. China Bio-imaging Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BaySpec, Inc.
  • 18.6. Bracco S.p.A.
  • 18.7. Bruker Corporation
  • 18.8. Canon Medical Systems Corporation
  • 18.9. Digirad Corporation
  • 18.10. Esaote S.p.A
  • 18.11. Fujifilm Holdings Corporation
  • 18.12. GE HealthCare Technologies, Inc.
  • 18.13. Hitachi Medical Corporation
  • 18.14. HT BioImaging Ltd
  • 18.15. iThera Medical GmbH
  • 18.16. Kitware, Inc.
  • 18.17. Koninklijke Philips N.V.
  • 18.18. Lantheus Medical Imaging, Inc.
  • 18.19. M Squared Lasers Ltd.
  • 18.20. MARS Bioimaging Limited
  • 18.21. Medtronic PLC
  • 18.22. MobileODT Ltd by Liger Medical LLC
  • 18.23. Perspectum Ltd.
  • 18.24. Quibim, S.L.
  • 18.25. RadNet, Inc.
  • 18.26. Rivanna Medical, Inc.
  • 18.27. Samsung Medison Co., Ltd.
  • 18.28. Siemens Healthineers

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIO-IMAGING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIO-IMAGING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIO-IMAGING MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIO-IMAGING MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIO-IMAGING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIO-IMAGING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIO-IMAGING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIO-IMAGING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIO-IMAGING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGING SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIO-IMAGING MARKET SIZE, BY CT SCANNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIO-IMAGING MARKET SIZE, BY MRI MACHINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIO-IMAGING MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIO-IMAGING MARKET SIZE, BY DATA MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIO-IMAGING MARKET SIZE, BY IMAGE ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIO-IMAGING MARKET SIZE, BY ENDOSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIO-IMAGING MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIO-IMAGING MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIO-IMAGING MARKET SIZE, BY SURGICAL MICROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIO-IMAGING MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIO-IMAGING MARKET SIZE, BY X-RAY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIO-IMAGING MARKET SIZE, BY 2D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIO-IMAGING MARKET SIZE, BY 3D IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIO-IMAGING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIO-IMAGING MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIO-IMAGING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIO-IMAGING MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL BIO-IMAGING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL BIO-IMAGING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIO-IMAGING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIO-IMAGING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BIO-IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 92. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 102. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 103. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BIO-IMAGING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. GCC BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. G7 BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. G7 BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 181. G7 BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 182. G7 BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. NATO BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 188. NATO BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 189. NATO BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 191. NATO BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL BIO-IMAGING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BIO-IMAGING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BIO-IMAGING MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BIO-IMAGING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BIO-IMAGING MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BIO-IMAGING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BIO-IMAGING MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA BIO-IMAGING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BIO-IMAGING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)